Six DMD Researches You Should Follow up in 2026

Despite significant advancements over the past ten years for DMD patients, there is still a significant unmet demand. In order to meet the need, a number of businesses, such as Satellos, Regenxbio, Wave, Dyne, and Avidity, are developing experimental treatments that aim for increased effectiveness and wider accessibility.

2026 could be a breakout year for the Duchenne muscular dystrophy field. While several therapies have entered the market in recent years, there is still a significant unmet need for children living with DMD. But with several companies advancing next-generation treatments and the industry now having established regulatory pathways, experts say new options are on the horizon.

A number of businesses, such as Satellos, Dyne, Avidity, and Wave Life Sciences, are currently working to respond to this need. Given the development of a new generation of exon skipping therapies and the gene therapies offered by Regenxbio and Solid Bio, there is good reason to think that further DMD treatments may soon be available. >> Read More: Next Generation Exon Skipping Therapies for DMD

- Follow Us -

Satellos: SAT-3247

Satellos announced the commencement of a Phase 2A trial of SAT-3247 (NCT07287189) in ambulatory patients with Duchenne aged 7 to 10 years. In this trial, two doses of SAT-3247 will be studied over 12 weeks in a randomized, double-blind, placebo-controlled, intraweek regimen to determine the optimal dose, safety, tolerance, and preliminary efficacy. >> Learn More: Phase 2A (BASECAMP) Study of SAT-3247

Regenxbio: RGX-202

With RGX-202, which is presently undergoing a pivotal research phase , Regenxbio is vying for Sarepta’s Elevidys in the gene therapy market.

Thirty patients who are one year of age or older are being recruited for the experiment, making the total population younger than Elevidys’ existing label. According to Kelly, first findings from a small group of patients published in November 2024 were “extremely encouraging,” showing improvements in strength and time function tests along with a solid safety profile. In 2026, Regenxbio anticipates submitting a BLA.

The size of the DMD gene, which is just too big for the AAV delivery vehicle, is a major obstacle for gene therapy in this field, according to Kelly. As a result, a shortened form is used, but its end product is unable to function as well as the full-sized protein. Compared to Elevidys, Regenxbio’s architecture permits a somewhat larger version of the gene.

Kelly is eager to see the results of a previous trial extended to a greater number of patients. If effective, he thinks it will give parents searching for a DMD gene therapy another option and chance. >> Learn More: REGENXBIO Announces Completion of RGX-202 Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Avidity Biosciences: Del-Zota

By focusing on exon 44, for which there are presently no approved medications, Avidity may be able to provide treatment for the 6% of DMD patients who are susceptible to exon 44 skipping.

According to Michael Kelly, chief scientific officer of CureDuchenne, delpacibart zotadirsen (del-zota) enhanced dystrophin production in DMD patients to a staggering 25% of normal function in a Phase I/II trial. This is some of the best exon skipping evidence observed from any medication. Additionally, Del-Zota brought creatine kinase down to almost normal levels.

The business intends to submit a BLA in mid-2026, and more results from the Explore44 open-label extension study is anticipated this year. Del-Zota has already received fast-track classification and orphan drug designation from the FDA. >> Keep Reading: Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota (Exon 44 Skipping)

Capricor Therapeutics: Deramiocel

The FDA is now reviewing a biologics license application for Capricor’s allogeneic cell treatment for DMD cardiomyopathy. >> Read More: Pivotal Phase 3 HOPE-3 Study of Deramiocel in DMD

If approved, Deramiocel would be the first drug to specifically treat DMD cardiomyopathy. Nearly all patients develop heart problems by adulthood, making it the primary cause of death from the disease. Based on agency input, Capricor has applied for full FDA approval, which is unusual in the DMD market because most drugs are approved through the FDA’s accelerated approval program. >> Read More: What is Deramiocel?

Dyne Therapeutics: Dyne-251

In order to obtain fast approval for its next-generation exon 51 skipping therapy, Dyne-251, based on FDA input, Dyne is now recruiting for a pivotal trial. Dystrophin expression will be used as a surrogate endpoint. >> Read More: Dyne Therapeutics to Apply for Accelerated Approval in Q2 2026 for Exon 51 Skipping Therapy (DYNE-251)

Wave Life Sciences: WVE-N531

After evaluating patients’ needs, Wave Life Sciences CEO Paul Bolno said that the way to a more successful treatment was improved cell distribution for higher dystrophin production and consistent expression.

The Phase II study’s six-month interim analysis revealed that Wave’s WVE-N531 (an exon 53 skipping) consistently displayed 9% dystrophin expression in all patients. This resulted in healthier-looking muscle and reduced blood levels of creatine kinase, a biomarker for muscle injury, according to Bolno. >> Read More: WVE-N531 Exon Skipping Therapy Phase 2 Clinical Trial Begins for Duchenne Muscular Dystrophy

Read More: Clinical Trials for Duchenne (List of All Researches)

- Follow Us -